Natural Interventions for Posttreatment Cancer-related Fatigue

Spotlight on ginseng, Rhodiola, and medicinal mushrooms

By Lise Alschuler, ND, FABNO, and Karolyn A. Gazella

Printer Friendly PagePrinter Friendly Page

Abstract

While percentages vary, studies have consistently demonstrated that cancer-related fatigue is one of the most common debilitating side effects associated with both radiation and chemotherapy, as well as the malignant process itself. Quality of life can be significantly and negatively impacted in cancer survivors who experience fatigue and other commonly associated symptoms including sleep disturbance, pain, depression, and anxiety. Presently, pharmacological options are limited and are often associated with further side effects. An integrative approach that, in addition to optimizing lifestyle, employs specific natural agents can safely and effectively enhance energy levels following conventional cancer treatments. While much of the data associated with these natural interventions are considered preliminary, the benefit-to-risk profile is appealing and thus should be considered in clinical practice. While there are many ways to mitigate symptoms, including fatigue, during active conventional treatment, the focus of this article is on posttreatment cancer-related fatigue. 

Introduction

The fatigue associated with cancer or cancer treatment is broadly referred to as cancer-related fatigue (CRF). The National Comprehensive Cancer Network defines CRF as persistent, subjective fatigue that interferes with the patient’s ability to carry out normal daily activities.1 This is different than other forms of fatigue such as overexertion or flu-related fatigue, which are typically resolved with rest and sleep. In cases of CRF, the fatigue becomes pathological when it occurs during normal activities, does not improve, and severely impacts a patient’s quality of life.
 
A multicenter patient survey conducted by Stone et al demonstrated that CRF affects more patients for a longer period of time than any other posttreatment symptom and that patients view this symptom as being more significant than any other symptom, including pain or nausea.2 The authors also report that CRF is consistently underreported and often untreated.
 
Because of its subjective nature and the broad definition often used in clinical studies, CRF prevalence data vary. Hofman et al reported that up to 80% of patients treated with chemotherapy experienced fatigue, and up to 90% of those treated with radiation experienced fatigue.3 These percentages are consistent with other research.4 A small study by Nail et al showed that 81% of the patients who had received chemotherapy reported fatigue as a significant side effect.5
 
The onset of CRF typically coincides with treatment but in as many as 40% of patients, it can start as an early symptom of malignancy beginning prediagnosis.3 CRF can persist for months or even years after treatment ends. Bower et al reported in 2006 that 34% of their breast cancer study participants had significant fatigue even 5 to 10 years after diagnosis.6 Another study involving patients who had a previous diagnosis of Hodgkin’s lymphoma found that fatigue was still present in 60% of the participants even 5 years after diagnosis.7 A more recent study by Oerlemans et al reported that 44% to 54% of non-Hodgkin’s lymphoma patients reported constant fatigue 10 years postdiagnosis.8 In some cases, especially during active chemotherapy and radiation, there is a large subset of patients who experience an energy pattern with sharp dips and plateaus sometimes referred to as “roller coaster” fatigue.9
 
While reporting of fatigue can be subjective, it is often accompanied by objective physical symptoms such as pain, weakness, depression, nausea, impaired cognitive function, and sleep disturbance.4,10
 
There are several comorbid factors and other issues that can increase a patient’s risk of developing CRF11,12:
  • advanced age, 
  • advanced disease,
  • previous conventional treatment,
  • pain,
  • electrolyte and fluid disturbances,
  • anemia,
  • cachexia,
  • nutrient deficiencies,
  • insomnia,
  • depression and/or anxiety,
  • high body mass index, and
  • lack of physical activity.
 
Comorbidity and a lack of clear etiological mechanisms make this condition multifactorial and more complex to treat and reverse. 

Possible Underlying Mechanisms

Causal factors associated with CRF are not fully understood; however, it is becoming clear that the etiology of posttreatment fatigue is related, at least in part, to underlying mechanisms associated with activation of the proinflammatory cytokine network, hypothalamic-pituitary-adrenocortical (HPA) axis dysfunction, circadian rhythm disruption, and mitochondrial dysregulation.13,14
 
The contribution of inflammatory cytokines to CRF has been demonstrated in a number of investigational studies. Collado-Hidalgo et al (2008) examined single nucleotide polymorphisms in fatigued and nonfatigued breast cancer survivors and found that polymorphisms in the interleukin-(IL) 1β genotype may be a potential risk factor in the development of CRF.14 Previously, these same researchers demonstrated that circulating inflammatory markers and functional alterations in the proinflammatory cytokine network were associated with increased fatigue in breast cancer survivors.15 Higher levels of c-reactive protein and IL-6 have also been correlated with the presence of fatigue in women diagnosed with breast cancer before the initiation of treatment,16 suggesting that the inflammatory underpinnings are the result of the malignancy itself and perhaps later aggravated by treatment. Bower et al (2011) demonstrated that fatigue was positively associated with higher plasma levels of soluble tumor necrosis factor receptor II in breast cancer patients who were treated with chemotherapy (P<0.05).13 In that study, 25% of the participants also reported elevated depressive symptoms and 60% reported corresponding sleep disturbances; however, increased inflammatory markers were not correlated with those 2 comorbid factors. Cytokine and IL-mediated fatigue has been postulated to be the result of cytokine-induced central nervous system (CNS) inflammation that in turn alters hypothalamic and hippocampal functioning.17
 
One result of hypothalamic and hippocampal dysfunction is disruption of the HPA axis. HPA axis dysfunction, aggravated by the inflammatory stress of cancer treatment, as well as the psychological distress associated with a cancer diagnosis, is proposed as a discrete cause of post–cancer treatment fatigue. Chemotherapy and radiation are known to alter HPA axis function leading to endocrine alterations that can cause fatigue.18 In a study involving children with brain cancer, Schmiegelow et al demonstrated that radiation and chemotherapy negatively impacted HPA axis function that resulted in secondary adrenal insufficiency.19 Preliminary studies indicate that reduced cortisol output and disturbances in HPA axis function correlate with CRF.18 Bower et al (2002) also demonstrated that CRF was associated with reduced cortisol output in breast cancer survivors.20
The loss of the sleep-wake cycle in cancer survivors may also represent a central mechanism for fatigue, insomnia, and depression/anxiety.
Endocrine disruption and circadian rhythm are closely related. Alterations in circadian function as it relates to CRF are linked in part to cortisol secretion. Bower et al (2005) demonstrated that breast cancer survivors with CRF had a significantly flatter diurnal cortisol slope when compared to women without fatigue and that the severity of the fatigue correlated closely with the flatter slope plots.21 Rich et al demonstrated that patients with inconsistent and/or dampened circadian rhythms also had greater fatigue compared to patients with better-defined rhythms.22 This reflects a heightened hypothalamic sensitivity to the negative feedback of cortisol or more likely, given the cytokine-induced CNS inflammation, a reduced central HPA axis drive and impaired responsiveness. The loss of the sleep-wake cycle in cancer survivors may also represent a central mechanism for fatigue, insomnia, and depression/anxiety experienced by some cancer survivors.
 
Mitochondrial dysregulation is also a logical contributing factor for CRF.23 One of the characteristics of cytotoxic cancer therapies is the generation of high levels of oxidative stress.24 High levels of intracellular oxidative stress cause cellular hypoxia that limits oxidative phosphorylation in the mitochondrial inner membrane, the primary cellular process used to generate adenosine triphosphate (ATP). This inhibition of mitochondrial oxidative phosphorylation can occur as a result of oxidatively induced mitochondrial fission and ultimately mitochondrial uncoupling.25 Another oxidatively mediated cause of reduced oxidative phosphorylation is direct impairment of the electron transport chain,26 primarily the result of oxidative damage to mitochondrial DNA along with ubiquinone deficiency.27 Furthermore, several drugs used in cancer treatment, such as anthracyclines, damage mitochondria and inhibit mitochondrial biogenesis,28 thereby stunting cellular energy recovery posttreatment.
 
Successfully impacting and even reversing CRF requires attention to the potential underlying mechanistic factors. Fortunately, there are several botanicals and nutrients that may positively influence posttreatment CRF. Adaptogenic herbs are among the most potentially impactful strategies in the alleviation of CRF. 
 

Botanical Adaptogens

The primary mechanism of action of botanical adaptogens is to normalize the output of the HPA axis. Most adaptogens increase adrenocorticotropic hormone (ACTH) and cortisol with single high-dose administration and normalize ACTH and cortisol with longer-term administration.29 The use of adaptogens causes normalization of stress-induced alteration in plasma corticosterone and monoamines such as norepinephrine, 5-hydroxytryptamine, and dopamine in the cortex and hippocampus regions of the brain.30 Another key point of action of adaptogens appears to be their upregulating and stress-mimetic effects on the “stress-sensor” 70 kilodalton heat shock proteins, which interact with glucocorticoid receptors and, in so doing, affect the levels of circulating cortisol and nitric oxide (NO).31 Prevention of stress-induced increases in NO and the associated decrease in ATP production, results in increased performance and endurance.31 Adaptogens specifically can increase energy and stamina, improve mood, and enhance cognition.32

Ginseng

Ginseng has been used in Asian countries for thousands of years. The active medicinal components of the plants are ginsenosides. There are 2 major species of ginseng: Asian/Korean ginseng (Panax ginseng) and American ginseng (Panax quinquefolius). Both species have similar constituents, including ginsenosides Rb1 and Rg1. P ginseng is one of the most researched ginsengs and has been shown to have anti-inflammatory, antioxidant, and anticancer effects with clinical research also revealing that it can improve psychological and immune function.33,34
 
Safety data regarding P ginseng demonstrate good toleration with mild adverse events such as dyspepsia, hot flash, insomnia, and constipation being reported.35 There are no confirmed drug-botanical interactions; however, P ginseng does induce cytochrome P450, family 3, subfamily A (CYP3A) and therefore caution with drugs that are CYP3A substrates is advised.36 Additionally, use during pregnancy and lactation should be avoided.34 Preliminary data show that ginseng can offer protection against cancer37 and while there are no human studies on the interaction of ginseng with chemotherapy or radiation, preclinical studies indicate synergism of P ginseng with various chemotherapeutics.38 Some caution is warranted in presence of estrogen receptor–positive cancer as in vitro assays have demonstrated estrogen-receptor activation and proliferation effects of human breast cancer cells.39
 
A literature review by Choi et al revealed 1,415 relevant studies with 30 randomized clinical trials and found that although many of the studies were poorly designed, ginseng appears to be effective for a variety of conditions.40 Kim et al found that P ginseng (1 g/d or 2 g/d) reduced fatigue severity in patients with idiopathic chronic fatigue compared to placebo; however, this failed to reach statistical significance (P>0.05).41 Nonetheless, the interesting aspect of another study was the noteworthy antioxidant effects that were measured in the P ginseng group.42 In that study, reactive oxygen species and malondialdehyde were lowered and total glutathione was increased significantly when compared to placebo. The researchers concluded that the antifatigue effects of P ginseng are due in part to its antioxidant properties, perhaps favorably impacting mitochondrial function.
 
A pilot study conducted by Kim et al looked at quality of life (QoL) scores in cancer patients. After 12 weeks, the patients who took 3,000 mg of P ginseng showed improvement in mental and physical functioning compared to placebo as indicated by subjective QoL scores.41 Improvement in QoL could be due in part to the demonstrated anxiolytic effects ginsenosides have by their interactions with GABA receptors.43
 
Specific to CRF, a randomized, double-blind, multisite trial featuring fatigued cancer survivors conducted by Barton et al demonstrated that P quinquefolius at a dose of 2,000 mg daily for 8 weeks produced statistically significant improvement in fatigue scores compared to placebo (P=0.003).44

Rhodiola 

Rhodiola rosea is a traditional botanical medicine that has been used for centuries to increase physical endurance, improve resistance to altitude sickness, enhance longevity, and treat depression, anemia, fatigue, and other health issues. Scientific research on this botanical has increased dramatically over the past several decades. Since 1960, there have been more than 180 different Rhodiola studies published in the scientific literature.45 The majority of these studies were done on the R rosea species of the genus Rhodiola, and most of the human studies utilized a standardized dose that contained 3% rosavins and 0.8% to 1% salidroside, which coincides with the naturally occurring ratio of 3:1 in R rosea.45,46
 
From a mechanistic standpoint, R rosea has different effects on the CNS depending on dose. Larger doses have a more sedative effect while smaller doses promote the release of brain monoamines, which then activate the cerebral cortex and limbic system.47
 
R rosea is considered safe because of its low toxicity level and low side effects profile, although dizziness and dry mouth have been reported in a clinical trial setting.48 A review by Ishaque et al concluded that there are few side effects associated with R rosea supplementation and that adverse effects such as headache and insomnia were mild and rare.46 Specific to cancer, preliminary in vivo studies have shown that R rosea may enhance the effects of chemotherapy in general and potentially reduce universal side effects such as fatigue and cognitive impairment.45 Animal studies have failed to show interactive effects between Rhodiola and medications, although Rhodiola may contribute to hypoglycemia and hypotension.49
 
There have been no studies conducted to date specifically involving patients with CRF; however, there have been several human clinical trials evaluating efficacy in both mental and physical fatigue. Olsson et al looked at individuals suffering from stress-related fatigue in a randomized, double-blind, parallel-group study and found that R rosea decreased cortisol response to stress and had a positive effect on fatigue levels when compared to placebo.50 The study also demonstrated that there were improvements in cognitive function when patients receiving the extract were placed under stressful conditions.
 
The review of 11 clinical trials by Ishaque et al found contradictory evidence due to study bias or reporting flaws. While results were inconsistent, 2 of the 6 trials looking at physical fatigue demonstrated R rosea to be effective and 3 of the 5 studies evaluating R rosea for mental fatigue showed that it was effective.46
 
Preliminary animal data also indicate that R rosea has cytokine-reducing antiinflammatory properties, which could explain in part how it can help reverse mental and physical fatigue. Lee et al found that oral administration in vivo suppressed several proinflammatory factors including IL-1B, inducible nitric oxide synthase (iNOS), and tumor necrosis factor (TNF-a).51 The same study showed a neuroprotective effect from R rosea as well. 

Medicinal Mushrooms

Mushrooms have a long history of use as medicines in many cultures. Many of these mushrooms are immunomodulators that can help prevent and treat many illnesses. Mushrooms have also been shown to produce antiinflammatory effects by downregulation of iNOS, cytochrome c oxidase-2, IL-1B, and TNF-a.52 The safety profile of these medicinal mushrooms is also very positive.53 In addition to their anticancer effects, some mushrooms have been shown to increase the cytotoxic effects of chemotherapy.54
 
Mushrooms are biological response modifiers, so their overall therapeutic actions may benefit cancer survivors who are experiencing chronic fatigue. Animal studies have demonstrated various mechanisms by which mushrooms improve energy. One study found that a mushroom extract increases endurance by increasing liver and muscle glycogen deposition.55 Another animal study found that an extract of Ganoderma lucidum enhances Krebs cycle dehydrogenases and mitochondrial electron transport chain complex IV activities, thereby contributing to increased cellular energy.56 A 3-month double-blinded clinical trial of 7 healthy male cyclists demonstrated increased free radical scavenger capacity in the athletes’ serum after daily dosing of 1,335 mg standardized extract of Cordyceps sinensis and 1,170 mg pure extract of Ganoderma lucidum. This effect correlated with enhanced recovery and overall performance.57 A 1-year randomized control trial of 73 obese adults assessed various metabolic impacts of substituting meat with mushroom in the diet. At the end of a year, participants on the mushroom diet experienced weight loss, lower body mass index, and improved lipid and inflammatory markers.58These improvements are consistent with improved metabolism and energy.
 
Of note, mushroom extracts exert significant immune-enhancing activities and a meta-analysis by Eliza et al demonstrated that Coriolus versicolor produced a 9% absolute reduction in 5-year mortality in cancer patients, which equated to 1 additional patient alive for every 11 patients treated.59 All trials used mushroom extracts standardized to 1 g to 3.6 g of polysaccharide-K or polysaccharide peptide daily with range duration of therapy from 1 month to 36 months. The trials included patients with cancers of the nasopharynx, breast, colorectum, stomach, and esophagus.

Nutrient Support

One of the key roles that nutrients have in energy regeneration is to reduce inflammatory cytokines and to optimize mitochondrial function. While an exhaustive list is beyond the scope of this article, the following deserve mention.  
  • Acetyl-L-carnitine: Supports oxidative phosphorylation from fatty acids. Fatty acids in cytoplasm are transformed to long-chain acyl-coenzyme A (CoA) and 3 carnitine-dependent enzymes transfer the fatty acids into the mitochondrial matrix where they undergo beta-oxidation to produce acetyl-CoA, which enters the Kreb’s cycle.60
  • Alpha lipoic acid: Studies performed in rats have also shown that supplementation with alpha-lipoic-acid and acetyl-L-carnitine synergistically reduced oxidative stress and improved mitochondrial function.61
  • CoenzymeQ10 (as ubiquinol): CoQ10 is an integral component of the electron transport chain, and it modulates mitochondrial permeability and is thus necessary for optimal mitochondrial function. Of note, a recent randomized, double-blind, placebo-controlled study of 300 mg of oral CoQ10 (as ubiquinol) failed to show relief of self-reported treatment-related fatigue in newly diagnosed patients with breast cancer when taken for 24 weeks concurrent with chemotherapy.62 The favorable impact of CoQ10 may be more evident when ubiquinone levels are depleted (ie, posttreatment). 

Discussion

There is no question that CRF is a significant problem for many cancer survivors and it is absolutely critical that it be addressed in clinical practice. The integrative practitioner—whether in general practice, naturopathic oncology, or any form of complementary medicine—can play an important role in filling the gap for these patients.
 
A treatment strategy should begin by assessing and addressing potential underlying causal factors associated with activation of the proinflammatory cytokine network, HPA axis dysfunction, circadian rhythm disruption, and mitochondrial dysregulation. There are many tools that address these underlying factors, including the botanical adaptogens P ginseng and R rosea, medicinal mushrooms, and mitochondrial nutrients. In addition to these supplemental strategies, regular exercise, optimal nutrition, and stress management should also be considered in this patient population.

Conflict of Interest Disclosure

Lise Alschuler, ND, FABNO, is an independent contractor providing educational services to healthcare and dietary supplement companies and nonprofit professional associations. She is on the Medical Advisory Board of Integrative Therapeutics and the Executive Director of TAP Integrative, an educational non-profit that receives sponsorship support from Integrative Therapeutics. She is also a co-principle of Thrivers, LLC, a multimedia consumer educational corporation that derives a percentage of revenue from sponsorships and consultation services associated with dietary supplement products.
 
Karolyn A. Gazella provides educational consulting services to healthcare and dietary supplement companies and is a co-principle of Thrivers, LLC, a multimedia consumer educational corporation that derives a percentage of revenue from sponsorships and consultation services associated with dietary supplement products.

About the Authors

Lise Alschuler, ND, FABNO, is a naturopathic physician with board certification in naturopathic oncology. She maintains a part-time naturopathic oncology practice with Naturopathic Specialists in Scottsdale, Arizona. Her undergraduate degree in medical anthropology is from Brown University and her naturopathic doctorate is from Bastyr University. She is the coauthor of The Definitive Guide to Cancer and The Definitive Guide to Thriving After Cancer. Alschuler is the chief medical officer of the iTHRIVE Plan.

Karolyn A. Gazella has been writing and publishing integrative health information since 1992. She is the publisher of the Natural Medicine Journal and the author or coauthor of hundreds of articles and several booklets and books including her latest book The Definitive Guide to Thriving After Cancer that she wrote with Lise Alschuler, ND, FABNO. Gazella is the co-creator and Chief Executive Officer of the iTHRIVE Plan, an innovative online wellness program specifically for cancer survivors.

References

  1. Mock V, Atkinson A, Barsevick A, et al. NCCN Practice Guidelines for Cancer-Related Fatigue. Oncology (Williston Park). 2000;14(11A):151-161.
  2. Stone P, Richardson A, Ream E, et al. Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Cancer Fatigue Forum. Ann Oncol. 2000;11(8):971-975.
  3. Hofman M, Ryan JL, Figueroa-Moseley CD, Jean-Pierre P, Morrow GR. Cancer-related fatigue: the scale of the problem. Oncologist. 2007;12 Suppl 1:4-10.
  4. Morrow GR. Cancer-related fatigue: causes, consequences, and management. Oncologist. 2007;12 Suppl 1:1-3.
  5. Nail LM, Jones LS, Greene D, Schipper DL, Jensen R. Use and perceived efficacy of self-care activities in patients receiving chemotherapy. Oncol Nurs Forum. 1991;18(5):883-887.
  6. Bower JE, Ganz PA, Desmond KA, et al. Fatigue in long-term breast carcinoma survivors: a longitudinal investigation. Cancer. 2006;106(4):751-758.
  7. Campos MP, Hassan BJ, Riechelmann R, DelGiglio A. Cancer-related fatigue: a practical review. Ann Oncol. 2011;22(6):1273-1279. Epub 2011 Feb 16.
  8. Oerlemans S, Mols F, Issa DE, et al. A high level of fatigue among long-term survivors of non-Hodgkin’s lymphoma: results from the longitudinal population-based PROFILES registry in the south of the Netherlands. Haematologica. 2013;98(3):479-486.
  9. Jean-Pierre P, Figueroa-Moseley CD, Kohli S, et al. Assessment of cancer-related fatigue: implication for clinical diagnosis and treatment. Oncologist. 2007;12 Suppl 1:11-21.
  10. Savard J, Simard S, Blanchet J, Ivers H, Morin CM. Prevalence, clinical characteristics, and risk factors for insomnia in the context of breast cancer. Sleep. 2001;24(5):583-590.
  11. Dimeo FC. Effects of exercise on cancer-related fatigue. Cancer. 2001;92(6 Suppl):1689-1693.
  12. Piper BF, Cella D. Cancer-related fatigue: definitions and clinical subtypes. J Natl Comp Canc Netw. 2010;8(8):958-966.
  13. Bower JE, Ganz PA, Irwin MR, Kwan L, Breen EC, Cole SW. Inflammation and behavioral symptoms after breast cancer treatment: do fatigue, depression, and sleep disturbance share a common underlying mechanism? J Clin Oncol. 2011;29(26):3517-3522.
  14. Collado-Hidalgo A, Bower JE, Ganz PA, Irwin MR, Cole SW. Cytokine gene polymorphisms and fatigue in breast cancer survivors: early findings. Brain Behav Immun. 2008;22(8):1197-1200.
  15. Collado-Hidalgo A, Bower JE, Ganz PA, Cole SW, Irwin MR. Inflammatory biomarkers for persistent fatigue in breast cancer survivors. Clin Cancer Res. 2006;12(9):2759-2766.
  16. Pertl MM, Hevey D, Boyle NT, et al. C-reactive protein predicts fatigue independently of depression in breast cancer patients prior to chemotherapy. Brain Behav Immun. 2013 Nov;34:108-119. 
  17. Wood LJ, Weymann K. Inflammation and neural signaling: etiologic mechanisms of the cancer treatment-related symptom cluster. Curr Opin Support Palliat Care. 2013 Mar;7(1):54-59. 
  18. Ryan JL, Carroll JK, Ryan EP, Mustian KM, Fiscella K, Morrow GR. Mechanisms of cancer-related fatigue. Oncologist. 2007;12 Suppl 1:22-34.
  19. Schmiegelow M, Feldt-Rasmussen U, Rasmussen AK, Lange M, Poulsen HS, Müller J. Assessment of the hypothalamo-pituitary-adrenal axis in patients treated with radiotherapy and chemotherapy for childhood brain tumor. J Clin Endocrinol Metab. 2003;88(7):3149-3154.
  20. Bower JE, Ganz PA, Aziz N, Fahey JL. Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom Med. 2002;64(4):604-611.
  21. Bower JE, Ganz PA, Dickerson SS, Petersen L, Aziz N, Fahey JL. Diurnal cortisol rhythm and fatigue in breast cancer survivors. Psychoneuroendocrinology. 2005;30(1):92-100.
  22. Rich T, Innominato PF, Boerner J, et al. Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer. Clin Cancer Res. 2005;11(5):1757-1764.
  23. Boland M, Chourasia A, Macleod K. Mitochondrial dysfunction in cancer. Front Oncol. 2013 Dec 2;3:292.
  24. Gilliam LA, St Clair D. Chemotherapy-induced weakness and fatigue in skeletal muscle: the role of oxidative stress. Antiox Redox Signal. 2011;15(9):2543-2563.
  25. Archer SL. Mitochondrial dynamics—mitochondrial fission and fusion in human diseases. N Engl J Med. 2013;369(23):2236-2251.
  26. Orsucci D, Filosto M, Siciliano G, Mancuso M. Electron transfer mediators and other metabolites and cofactors in the treatment of mitochondrial dysfunction. Nutr Rev. 2009;67(8):427-438. 
  27. Plecitá-Hlavatá L, Jezek J, Jezek P. Pro-oxidant mitochondrial matrix-targeted ubiquinone MitoQ10 acts as anti-oxidant at retarded electron transport or proton pumping within Complex I. Int J Biochem Cell Biol. 2009;41(8-9):1697-1707.
  28. Chan K, Truong D, Shangari N, O’Brien PJ. Drug-induced mitochondrial toxicity. Expert Opin Drug Metab Toxicol. 2005;1(4):655-669.
  29. Panossian A, Wagner H. Stimulating effect of adaptogens: an overview with particular reference to their efficacy following single dose administration. Phytother Res. 2005;19(10):819-838.
  30. Sheikh N, Ahmad A, Siripurapu KB, Kuchibhotla VK, Singh S, Palit G. Effect of Bacopa monniera on stress induced changes in plasma corticosterone and brain monoamines in rats. J Ethnopharmacol. 2007;111(3):671-676. 
  31. Panossian A, Wikman G. Evidence-based efficacy of adaptogens in fatigue, and molecular mechanisms related to their stress-protective activity. Curr Clin Pharmacol. 2009;4(3):198-219.
  32. Singh N, Bhalla M, de Jager P, Gilca M. An overview on ashwagandha: a Rasayana (rejuvenator) of Ayurveda. Afr J Tradit Complement Altern Med. 2011;8(5 Suppl):208-213. 
  33. Kiefer D, Pantuso T. Panax ginseng. Am Fam Physician. 2003;68(8):1539-1542.
  34. Lakshmi T, Roy A, Geetha RV. Panax ginseng: a universal panacea in the herbal medicine with diverse pharmacological spectrum—a review. Asian J Pharm Clin Res. 2011;4(Suppl 1):14-18.
  35. Lee N, Yoo S, Kim HG, Cho JH, Son CG.  Safety and tolerability of Panax ginseng root extract: a randomized, placebo-controlled, clinical trial in healthy Korean volunteers. J Altern Complement Med. 201218(11):1061-1069. 
  36. Malati CY, Robertson SM, Hunt JD, et al. Influence of Panax ginseng on cytochrome P450 (CYP)3A and P-glycoprotein (P-gp) activity in healthy participants. J Clin Pharmacol. 2012;52(6):932-939. 
  37. Yun TK, Choi SY. Preventive effect of ginseng intake against various human cancers: a case-control study on 1987 pairs. Cancer Epidemiol Biomarkers Prev. 1995;4(4):401-408.
  38. Duda RB, Zhong Y, Navas V, Li MZ, Toy BR, Alavarez JG. American ginseng and breast cancer therapeutic agents synergistically inhibit MCF-7 breast cancer cell growth. J Surg Oncol. 1999;72(4):230-239.
  39. King ML, Adler SR, Murphy LL. Extraction-dependent effects of American ginseng (Panax quinquefolium) on human breast cancer cell proliferation and estrogen receptor activation. Integr Cancer Ther. 2006;5(3):236-243.
  40. Choi J, Kim T-H, Choi T-Y, Lee MS. Ginseng for health care: a systematic review of randomized controlled trials in Korean literature. PLoS One. 2013;8(4):e59978.
  41. Kim JH, Park CY, Lee SJ. Effects of sun ginseng on subjective quality of life in cancer patients: a double-blind, placebo-controlled pilot trial. J Clin Pharm Ther. 2006;31(4):331-334.
  42. Kim HG, Cho JH, Yoo SR, et al. Antifatigue effects of Panax ginseng C.A. Meyer: a randomized, double-blind, placebo-controlled trial. PloS One. 2013;8(4):e61271.
  43. Park JH, Cha HY, Seo JJ, Hong JT, Han K, Oh KW. Anxiolytic-like effects of ginseng in the elevated plus-maze model: comparison of red ginseng and sun ginseng. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29(6):895-900.
  44. Barton DL, Liu H, Dakhil SR, et al. Wisconsin ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2. J Natl Cancer Inst. 2013;105(16):1230-1238.
  45. Brown RP, Gerbarg PL, Ramazanov Z. Rhodiola rosea: a phytomedicinal overview. HerbalGram. 2002;56:40-52.
  46. Ishaque S, Shamseer L, Bukutu C, Vohra S. Rhodiola rosea for physical and mental fatigue: a systemic review. BMC Complement Altern Med. 2012 May 19;12:70.
  47. Marina TF. Effect of Rhodiola rosea extract on bioelectrical activity of the cerebral cortex isolated to a different extent from the brain. In: Saratikov AS, Ed. Stimulants of the Central Nervous System. Tomsk, Soviet Union: Tomsk State University Press; 1968:27-31.
  48. Bystritsky A, Kerwin L, Feusner JD. A pilot study of Rhodiola rosea (Rhodax) for generalized anxiety disorder (GAD). J Altern Complement Med. 2008;14(2):175-180. 
  49. Panossian A, Hovhannisyan A, Abrahamyan H, Gabrielyan E, Wikman G. Pharmacokinetic and pharmacodynamic study of interaction of Rhodiola rosea SHR-5 extract with warfarin and theophylline in rats. Phytother Res. 2009;23(3):351-357. 
  50. Olsson EM, von Schéele B, Panossian AG. A randomized, double-blind, placebo-controlled, parallel-group study of the standardized extract SHR-5 of the roots of Rhodiola rosea in the treatment of subjects with stress-related fatigue. Planta Med. 2009;75(2):105-112.
  51. Lee Y, Jung J, Jang S, et al. Anti-inflammatory and neuroprotective effects of constituents isolated from Rhodiola rosea. Evid Based Complement Alternat Med. 2013;2013:514049.
  52. Lull C, Wichers HJ, Savelkoul HFJ. Antiinflammatory and immunomodulating properties of fungal metabolites. Mediators  Inflamm. 2005;2005(2):63-80.
  53. Wasser SP. Medicinal mushroom science: Current perspectives, advances, evidences, and challenges. Biomed J. 2014 Sep 2. [Epub ahead of print]
  54. Ji NF, Yao LS, Li Y, He W, Yi KS, Huang M. Polysaccharide of Cordyceps sinensis enhances cisplatin cytotocity in non-small cell lung cancer H157 cell line. Integr Cancer Ther. 2011;10(4):359-367.
  55. Huang CC, Hsu MC, Huang WC, Yang HR, Hou CC. Triterpenoid-rich extract from Antrodia camphorata improves physical fatigue and exercise performance in mice. Evid Based Complement Alternat Med. 2012;2012:364741. 
  56. Sudheesh NP, Ajith TA, Janardhanan KK. Ganoderma lucidum (Fr.) P. Karst enhances activities of heart mitochondrial enzymes and respiratory chain complexes in the aged rat. Biogerontology. 2009;10(5):627-636. 
  57. Rossi P, Buonocore D, Altobelli E, et al. Improving training condition assessment in endurance cyclists: Effects of Ganoderma lucidum and Ophiocordyceps sinensis dietary supplementation. Evid Based Complement Alternat Med. 2014;2014:979613. 
  58. Poddar KH, Ames M, Hsin-Jen C, Feeney MJ, Wang Y, Cheskin LJ. Positive effect of mushrooms substituted for meat on body weight, body composition, and health parameters. A 1-year randomized clinical trial. Appetite. 2013 Dec;71:3793-87. 
  59. Eliza WL, Fai CK, Chung LP. Efficacy of Yun Zhi (Coriolus versicolor) on survival in cancer patients: systematic review and meta-analysis. Recent Pat Inflamm Allergy Drug Discov. 2012;6(1):78-87.
  60. Calvani M, Reda E, Arrigoni-Martelli E. Regulation by carnitine of myocardial fatty acid and carbohydrate metabolism under normal and pathological conditions. Basic Res Cardiol. 2000;95(2):75-83.
  61. Parikh S, Saneto R, Falk MJ, et al. A modern approach to the treatment of mitochondrial disease. Curr Treat Options Neurol. 2009;11(6):414-430.
  62. Lesser GJ, Case D, Stark N, et al; Wake Forest University Community Clinical Oncology Program Research Base. A randomized, double-blind, placebo-controlled study of oral coenzyme Q10 to relieve self-reported treatment-related fatigue in newly diagnosed patients with breast cancer. J Support Oncol. 2013;11(1):31-42.